His nomination to head the HHS by President-elect Donald Trump on Thursday could bring sweeping changes to the way Washington, D.C., targets health issues.
Scientists at deCODE genetics and collaborators have published a study in the Journal of Allergy and Clinical Immunology ...
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Journal of Allergy and ...
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...